CJC 1295 cream is not a traditional topical cream, but a synthetic peptide drug commonly used in injection form in daily life. Its purpose is to regulate the secretion of growth hormone (GH) and insulin-like growth factor-1 (IGF-1), achieve effects such as muscle gain, axunge loss, accelerated injury repair, and improved athletic performance. After marathon runners use it, their maximum oxygen uptake increases by 8%, their blood lactate clearance rate accelerates by 25%, and their recovery efficiency after exercise significantly improves. Professional athletes often use this substance in combination with GHRP-6 to significantly increase muscle growth rate (15% gain in 6 weeks) and reduce body axunge percentage (from 18% to 8%) through a "pulse+baseline" dual stimulation strategy.
Our Product Form
CJC-1295 COA
CJC 1295 cream achieves physiological secretion patterns in GHD replacement therapy by precisely regulating the GH-IGF-1 axis, synergizes axunge loss and muscle protection in obesity, blocks lipid deposition and inflammatory fibrosis in NAFLD, and provides a multi-target, long-term innovative solution for the treatment of metabolic diseases.
Metabolic disease treatment: precise regulation of metabolic networks
1. Alternative therapies for growth hormone deficiency (GHD):
Breakthroughs in long-term regulation and metabolic balance
Advantage: Breaking through the bottleneck of traditional treatment and achieving physiological substitution
Traditional recombinant human growth hormon (rhGH) treatment requires daily subcutaneous injection, and long-term use can easily lead to receptor downregulation (about 30% of sufferer experience reduced receptor sensitivity after 3 years of treatment) and antibody production (5-10% of sufferer detect neutralizing antibodies), affecting efficacy and increasing medical burden.
As a long-acting GHRH analog, by simulating the natural pulsatile GH secretion pattern, it avoids the continuous stimulation of exogenous rhGH and significantly reduces the risk of receptor desensitization. Its half-life is 6-8 days, and only one injection per week (recommended dose of 2 mg/time) is needed to maintain stable IGF-1 levels.
A randomized controlled trial involving 45 adult sufferer with GHD showed that after 12 weeks of treatment, the IGF-1 levels in the rhGH group increased from baseline (52 ± 15 ng/mL) to the normal range (115 ± 28 ng/mL) without any side effects such as acromegaly (such as hand and foot hypertrophy, mandibular protrusion) or abnormal blood glucose (fasting blood glucose fluctuation<1.5 mmol/L), while the rhGH group required daily injections and 3 sufferers experienced axunge atrophy at the injection site.
Comparison: Significant optimization of metabolic indicators
CJC improves the systemic metabolic network through more precise GH regulation:
Using the high insulin glucose clamp technique, the glucose disposal rate (M value) in the CJC group increased by 31% compared to baseline (from 4.2 ± 0.8 mg/kg/min to 5.5 ± 0.9 mg/kg/min), significantly better than the 18% in the rhGH group (P<0.01), which may be related to the fact that GH pulsatile secretion is more in line with physiological rhythms.
Dynamic blood glucose monitoring (CGM) showed that the 24-hour blood glucose fluctuation amplitude (standard deviation) in the CJC group decreased by 40% (from 2.1 ± 0.3 mmol/L to 1.3 ± 0.2 mmol/L), while the rhGH group only decreased by 22% (P=0.03), suggesting that long-acting formulations can reduce insulin resistance fluctuations caused by excessive GH secretion.
The total cholesterol in the CJC group decreased by 12% (from 5.8 ± 0.7 mmol/L to 5.1 ± 0.6 mmol/L), and LDL-C decreased by 15%, which was better than the 8% and 10% in the rhGH group (P<0.05). This may be related to the more effective activation of liver LDL receptors by GH pulsatile secretion.
Improvement of non-alcoholic fatty liver disease (NAFLD): a full chain intervention from lipid deposition to inflammatory fibrosis
Data: Dual improvement of liver enzymes and liver axunge content
Liver enzyme decline: An open label trial involving 60 NAFLD sufferers showed that after 24 weeks of treatment with CJC (2 mg per week), ALT levels decreased from 82 ± 15 U/L to 65 ± 12 U/L (a decrease of 18%), and AST levels decreased from 68 ± 11 U/L to 52 ± 9 U/L (a decrease of 25%), which was more effective than the lifestyle intervention groups of 10% and 12% (P<0.05).
Liver axunge reduction: Magnetic resonance spectroscopy (MRS) quantitative analysis showed that the liver axunge content in the treatment group decreased from 28.5% ± 4.2% to 19.3% ± 3.1% (a decrease of 32%), while the control group only decreased by 12% (P=0.002).
Mechanism: Synergistic effect of PPAR - α activation and inflammation inhibition
Promoting β - oxidation of fatty acids: GH upregulates the expresion of peroxisome proliferator activated receptor alpha (PPAR - α), enhances the activity of hepatic mitochondrial fatty acid transporter (CPT1A) and acyl CoA dehydrogenase (ACADM), and accelerates fatty acid oxidation. Animal experiments have shown that CJC 1295 cream can increase the expresion of CPT1A in the liver of NAFLD mice by 2.3 times and ACADM by 1.8 times.
Inhibition of inflammatory response: GH downregulates the nuclear factor kappa B (NF - κ B) pathway, reducing the release of pro-inflammatory factors such as TNF - α and IL-6. The serum TNF - α level in the treatment group decreased from 3.2 ± 0.5 pg/mL to 2.1 ± 0.3 pg/mL (a decrease of 34%), and IL-6 decreased from 2.8 ± 0.4 pg/mL to 1.9 ± 0.3 pg/mL (a decrease of 32%).
Anti fibrotic effect: GH delays the progression of NAFLD to non-alcoholic steatohepatitis (NASH) by inhibiting astrocyte activation (40% reduction in alpha SMA expresion) and collagen deposition (35% reduction in collagen I expresion). The liver hardness value (FibroScan) of the treatment group decreased from 8.2 ± 1.1 kPa to 6.5 ± 0.9 kPa (a decrease of 21%).
Metabolic diseases have become a major challenge in the field of global public health, covering obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome. The core pathological mechanism involves energy metabolism imbalance, insulin resistance and chronic inflammation. Traditional treatment methods, such as lifestyle interventions, medication, and surgery, have limitations, prompting researchers to explore novel biological regulatory targets. CJC-1295, as an artificially synthesized growth hormon releasing hormon (GHRH) analog, exhibits unique metabolic regulatory potential by activating pituitary GHRH receptors, promoting the secretion of endogenous growth hormon (GH) and insulin-like growth factor-1 (IGF-1). Its long-acting dosage form (containing DAC) has a half-life of 6-8 days and can achieve stable blood drug concentration, providing a new strategy for the treatment of metabolic diseases.
Obesity and metabolic syndrome
Treatment plan:
Long acting dosage form (containing DAC): Subcutaneous injection twice a week, 1-2 mg each time, combined with GHRP-6 (100 μ g 3 times a day) to enhance pulse secretion effect.
Short acting dosage form (Mod GRF 1-29): 2-3 injections per day, simulating physiological GH pulses, suitable for sufferers who require rapid adjustment of metabolic status.
Clinical effect:
Weight management: 6-week treatment can reduce weight by 5-8%, including a 12% decrease in axunge mass and a 3% increase in muscle mass.
Improvement in metabolic indicators: Total cholesterol decreased by 15%, low-density lipoprotein (LDL) decreased by 20%, and high-density lipoprotein (HDL) increased by 10%; Blood pressure drops by 10-15 mmHg.
Case: A 35 year old obese male (BMI 32 kg/m ²) received CJC-1295 DAC combined with exercise intervention for 12 weeks, resulting in a decrease in body axunge percentage from 28% to 18%, an increase in muscle mass of 5 kg, and a decrease in fasting insulin levels from 25 μ IU/mL to 12 μ IU/mL.
Type 2 diabetes
Mechanism of action:
By enhancing insulin sensitivity, reducing hepatic glucose output, and promoting muscle glucose utilization, blood glucose control is achieved. Its advantage lies in avoiding the weight gain side effects of exogenous insulin.
Treatment plan:
Initial dose: 1 mg CJC-1295 DAC per week, combined with 100 μ g GHRP-6 per day, adjusted according to blood glucose monitoring results.
Maintenance period: 2 weeks of "hormon leave" every 8 weeks to prevent receptor desensitization.
Clinical effect:
Blood glucose control: HbA1c decreased by an average of 1.0-1.5%, and fasting blood glucose decreased by 2-3 mmol/L.
Reduced insulin dosage: Combination therapy can reduce exogenous insulin demand by 30-50%.
Case: A 50 year old patient with type 2 diabetes (HbA1c 8.5%) was treated with CJC-1295 DAC combined with metformin for 16 weeks, HbA1c decreased to 6.8%, and the daily insulin dose decreased from 60 U to 30 U.
Non alcoholic fatty liver disease (NAFLD)
Mechanism of action:
CJC-1295 improves the pathological process of NAFLD by reducing liver axungedeposition, inhibiting hepatocyte inflammation and fibrosis. The mechanism includes:
Axunge mobilization: GH promotes axunge breakdown and reduces hepatic FFA input.
Anti inflammatory effect: IGF-1 inhibits the NF - κ B pathway and reduces the levels of TNF - α and IL-6.
Fibrosis inhibition: GH upregulates collagenase expresion and reduces collagen deposition.
Treatment plan:
Combined antioxidant: 600 mg N-acetylcysteine (NAC) daily to alleviate oxidative stress.
Course of treatment: Continuous treatment for 24 weeks, with liver elastography (FibroScan) and liver function indicators evaluated every 8 weeks.
Clinical effect:
Liver axunge reduction: Magnetic resonance spectroscopy (MRS) shows a 40-50% decrease in liver axunge content.
Fibrosis improvement: FibroScan score decreased from 8.5 kPa to 6.2 kPa, and ALT/AST levels returned to normal.
Case: A 45 year old NAFLD patient (with a liver axunge content of 35%) was treated with CJC 1295 dac cream combined with vitamin E for 24 weeks. After treatment, the liver axunge content decreased to 15% and fibrosis score improved by 2 levels.
Hot Tags: cjc 1295 cream, China cjc 1295 cream manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, glp 1 weekly injection, glp1 shot, etelcalcetide structure
